Biomarkers in pediatric ARDS: Future directions

Frontiers in Pediatrics

Volumn 4, Issue JUN, 2016, Pages

  Orwoll, Benjamin E ^a   Sapru, Anil ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; ARDS; Biomarkers; Critical care; Molecular phenotypes; PARDS; Pediatrics; Surrogate outcomes

Indexed keywords

EID: 85032157084     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2016.00055     Document Type: Review

References (190)

1. Khemani RG, Markovitz BP, Curley MA. Characteristics of children intubated and mechanically ventilated in 16 PICUs. Chest (2009) 136:765-71. doi:10.1378/chest.09-0207
2. Erickson S, Schibler A, Numa A, Nuthall G, Yung M, Pascoe E, et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study. Pediatr Crit Care Med (2007) 8:317-23. doi:10.1097/01.PCC.0000269408.64179.FF
3. Hamvas A. Pathophysiology and management of respiratory distress syndrome. In: Martin R, Fanaroff A, Walsh M, editors. Fanarof & Martin's Neonatal-Perinatal Medicine, 9th Edition. St. Louis, MO: Elsevier (2011). p. 1106-16
4. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA (2012) 307:2526-33. doi:10.1001/jama.2012.5669
5. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med (1994) 149:818-24. doi:10.1164/ajrccm.149.3.7509706
6. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med (2015) 16:428-39. doi:10.1097/PCC.0000000000000350
7. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med (2000) 342:1334-49. doi:10.1056/NEJM200005043421806
8. Sapru A, Flori H, Quasney MW, Dahmer MK; Pediatric Acute Lung Injury Consensus Conference Group. Pathobiology of acute respiratory distress syndrome. Pediatr Crit Care Med (2015) 16:S6-22. doi:10.1097/PCC.0000000000000431
9. Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med (2005) 171:995-1001. doi:10.1164/rccm.200404-544OC
10. Yehya N, Servaes S, Thomas NJ. Characterizing degree of lung injury in pediatric acute respiratory distress syndrome. Crit Care Med (2015) 43:937-46. doi:10.1097/CCM.0000000000000867
11. Yehya N, Bhalla AK, Thomas NJ, Khemani RG. Alveolar dead space fraction discriminates mortality in pediatric acute respiratory distress syndrome. Pediatr Crit Care Med (2015) 17:101-9. doi:10.1097/PCC.0000000000000613
12. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD. Incidence and outcomes of pediatric acute lung injury. Pediatrics (2009) 124:87-95. doi:10.1542/peds.2007-2462
13. Bruijn M, Jansen EM, Klapwijk T, van der Lee JH, van Rijn RR, van Woensel JBM, et al. Association between C-reactive protein levels and outcome in acute lung injury in children. Eur J Pediatr (2013) 172:1105-10. doi:10.1007/s00431-013-2006-7
14. Hall MW, Geyer SM, Guo C-Y, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med (2013) 41:224-36. doi:10.1097/CCM.0b013e318267633c
15. Emboriadou M, Hatzistilianou M, Magnisali C, Sakelaropoulou A, Exintari M, Conti P, et al. Human neutrophil elastase in RSV bronchiolitis. Ann Clin Lab Sci (2007) 37:79-84
16. Ng PC, Lam CWK, Li AM, Wong CK, Cheng FWT, Leung TF, et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics (2004) 113:e7-14. doi:10.1542/peds.113.1.e7
17. Gauglitz GG, Finnerty CC, Herndon DN, Mlcak RP, Jeschke MG. Are serum cytokines early predictors for the outcome of burn patients with inhalation injuries who do not survive? Crit Care (2008) 12:R81. doi:10.1186/cc6932
18. Dobyns EL, Eells PL, Griebel JL, Abman SH. Elevated plasma endothelin-1 and cytokine levels in children with severe acute respiratory distress syndrome. J Pediatr (1999) 135:246-9. doi:10.1016/S0022-3476(99)70029-6
19. Schrama AJJ, Bernard A, Poorthuis BJHM, Zwinderman AH, Berger HM, Walther FJ. Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. Eur J Pediatr (2008) 167:1305-12. doi:10.1007/s00431-008-0713-2
20. Schwingshackl A, Kimura D, Rovnaghi CR, Saravia JS, Cormier SA, Teng B, et al. Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: results from a double-blind, placebo-controlled randomized pilot trial. Cytokine (2016) 77:63-71. doi:10.1016/j.cyto.2015.10.007
21. Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, et al. Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children. Pediatr Crit Care Med (2010) 11:82-91. doi:10.1097/PCC.0b013e3181ae5a4c
22. Blanco-Quirós A, Arranz E, Solis G, Garrote JA, Mayo A. High cord blood IL-10 levels in preterm newborns with respiratory distress syndrome. Allergol Immunopathol (Madr) (2004) 32:189-96. doi:10.1157/13064922
23. Ballabh P, Kumari J, Krauss AN, Shin JJ, Jain A, Auld PA, et al. Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. Pediatrics (2003) 111:461-8. doi:10.1542/peds.111.3.461
24. Lee YS, Kim S, Kang EK, Park JD. Antithrombin-III as an early prognostic factor in children with acute lung injury. Korean J Pediatr (2007) 50:443. doi:10.3345/kjp.2007.50.5.443
25. Sapru A, Curley MAQ, Brady S, Matthay MA, Flori H. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury. Intensive Care Med (2010) 36:157-63. doi:10.1007/s00134-009-1690-2
26. Sánchez Miralles A, Reig Sáenz R, Marco Vera P, Muñoz Pérez F, Alvarez Sánchez B, Sebastián Muñoz I. [Abnormalities in coagulation and fibrinolysis in septic shock with purpura]. An españoles Pediatr (2002) 56:99-103
27. Tunc T, Cekmez F, Yildirim S, Bulut O, Ince Z, Saldir M, et al. Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia. Pediatr Res (2014) 75:788-92. doi:10.1038/pr.2014.28
28. Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv Exp Med Biol (2015) 835:1-7. doi:10.1007/5584_2014_40
29. Wang K, Huang X, Lu H, Zhang Z. A comparison of KL-6 and Clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants. Dis Markers (2014) 2014:736536. doi:10.1155/2014/736536
30. Sarafidis K, Stathopoulou T, Diamanti E, Soubasi V, Agakidis C, Balaska A, et al. Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. Eur J Pediatr (2008) 167:1297-303. doi:10.1007/s00431-008-0712-3
31. Flori HR, Ware LB, Glidden D, Matthay MA. Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2003) 4:315-21. doi:10.1097/01.PCC.0000074583.27727.8E
32. Samransamruajkit R, Prapphal N, Deelodegenavong J, Poovorawan Y. Plasma soluble intercellular adhesion molecule-1 (sICAM-1) in pediatric ARDS during high frequency oscillatory ventilation: a predictor of mortality. Asian Pac J Allergy Immunol (2005) 23:181-8
33. Samransamruajkit R, Jiraratanawong K, Siritantiwat S, Chottanapan S, Deelodejanawong J, Sritippayawan S, et al. Potent inflammatory cytokine response following lung volume recruitment maneuvers with HFOV in pediatric acute respiratory distress syndrome. Asian Pac J Allergy Immunol (2012) 30:197-203
34. Al-Biltagi MA, Abo-Elezz AA, Abu-Ela KT, Suliman GA, Sultan TG. The prognostic value of soluble intercellular adhesion molecule 1 plasma level in children with acute lung injury. J Intensive Care Med (2015):1-6. doi:10.1177/0885066615605071
35. Briassoulis G, Mavrikiou M, Margeli A, Lazaropoulou C, Natsi L, Papassotiriou I, et al. Circulating levels of KL-6 in acute respiratory distress syndrome sepsis or traumatic brain injury in critically ill children. Pediatr Pulmonol (2006) 41:790-5. doi:10.1002/ppul.20465
36. Kawasaki Y, Aoyagi Y, Abe Y, Go H, Imamura T, Kaneko M, et al. Serum KL-6 levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis. J Med Virol (2009) 81:2104-8. doi:10.1002/jmv.21634
37. Garcia-Salido A, Onoro G, Melen GJ, Gomez-Pina V, Serrano-Gonzalez A, Ramirez-Orellana M, et al. Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study. Lung (2015) 193:19-23. doi:10.1007/s00408-014-9663-9
38. Wu R, Dai MY, Hu JH, Zha L, Tian ZF. Plasma level of soluble receptor for advanced glycation end products and aquaporin-5 in preterm infants with respiratory distress syndrome of newborn. Minerva Pediatr (2015)
39. Liu X, Chen Q, Shi S, Shi Z, Lin R, Tan L, et al. Plasma sRAGE enables prediction of acute lung injury after cardiac surgery in children. Crit Care (2012) 16:R91. doi:10.1186/cc11354
40. Zinter MS, Spicer A, Orwoll BE, Alkhouli M, Dvorak CC, Calfee CS, et al. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol (2015) 310:L224-31. doi:10.1152/ajplung.00336.2015
41. Al-Biltagi MA, Abo-Elezz AA, Elshafiey RMG, Suliman GA, Mabrouk MM, Mourad HA. The predictive value of soluble endothelial selectin plasma levels in children with acute lung injury. J Crit Care (2015) 32:31-5. doi:10.1016/j.jcrc.2015.12.012
42. Ramsay PL, O'Brian Smith E, Hegemier S, Welty SE. Early clinical markers for the development of bronchopulmonary dysplasia: soluble E-Selectin and ICAM-1. Pediatrics (1998) 102:927-32. doi:10.1542/peds.102.4.927
43. Kim BI, Lee HE, Choi CW, Jo HS, Choi EH, Koh YY, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia. J Perinat Med (2004) 32:282-7. doi:10.1515/JPM.2004.053
44. Benjamin ACW, Silveira RC, Procianoy RS. Umbilical cord blood and neonatal endothelin-1 levels in preterm newborns with and without respiratory distress syndrome. Brazilian J Med Biol Res (2005) 38:1417-22. doi:10.1590/S0100-879X2005000900017
45. Orwoll BE, Spicer AC, Zinter MS, Alkhouli MF, Khemani RG, Flori HR, et al. Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study. Crit Care (2015) 19:435. doi:10.1186/s13054-015-1145-9
46. Kalay S, Cakcak B, Oztekin O, Tezel G, Tosun O, Akcakus M, et al. The role of VEGF and its soluble receptor VEGFR-1 in preterm newborns of preeclamptic mothers with RDS. J Matern Fetal Neonatal Med (2013) 26:978-83. doi:10.3109/14767058.2013.766692
47. Laughon M, Bose C, Allred EN, O'shea TM, Ehrenkranz RA, VAN Marter LJ, et al. Patterns of blood protein concentrations of ELGANs classified by three patterns of respiratory disease in the first 2 postnatal weeks. Pediatr Res (2011) 70:292-6. doi:10.1203/PDR.0b013e3182274f35
48. Flori HR, Ware LB, Milet M, Matthay MA. Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2007) 8:96-101. doi:10.1097/01.PCC.0000257097.42640.6F
49. Mosbah AA, Abdellatif NA, Sorour EI, Awadallah MF. Serum SP-D levels as a biomarker of lung injury in children suffering of bronchopneumonia. J Egypt Soc Parasitol (2012) 42:25-32. doi:10.12816/0006291
50. Kawasaki Y, Endo K, Suyama K, Sato M, Ito M, Hashimoto K, et al. Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis. Pediatr Pulmonol (2011) 46:18-22. doi:10.1002/ppul.21270
51. Chu MA, Lee EJ, Park HJ, Lee KH, Kim WT, Chung HL. Increased serum surfactant protein-D in the infants with acute respiratory syncytial virus bronchiolitis. Allergy Asthma Respir Dis (2013) 1:235. doi:10.4168/aard.2013.1.3.235
52. Reel B, Oishi PE, Hsu JH, Gildengorin G, Matthay MA, Fineman JR, et al. Early elevations in B-type natriuretic peptide levels are associated with poor clinical outcomes in pediatric acute lung injury. Pediatr Pulmonol (2009) 44:1118-24. doi:10.1002/ppul.21111
53. Roe MFE, Bloxham DM, White DK, Ross-Russell RI, Tasker RTC, O'Donnell DR. Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis. Clin Exp Immunol (2004) 137:139-45. doi:10.1111/j.1365-2249.2004.02512.x
54. Friedman Z, Demers LM. Essential fatty acids, prostaglandins, and respiratory distress syndrome of the newborn. Pediatrics (1978) 61:341-7. doi:10.1177/1536504215596939
55. Kong MYF, Li Y, Oster R, Gaggar A, Clancy JP. Early elevation of matrix metalloproteinase-8 and-9 in pediatric ARDS is associated with an increased risk of prolonged mechanical ventilation. PLoS One (2011) 6:e22596. doi:10.1371/journal.pone.0022596
56. Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ. Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res (1996) 40:250-6. doi:10.1203/00006450-199608000-00010
57. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics (1996) 97:210-5
58. Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol (1997) 24:331-6. doi:10.1002/(SICI)1099-0496(199711)24:5<331::AID-PPUL5>3.3.CO;2-N
59. Choi CW, Kim BI, Kim HS, Park JD, Choi JH, Son DW. Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr (2006) 95:38-43. doi:10.1080/08035250500404085
60. Plötz FB, Vreugdenhil HA, Slutsky AS, Zijlstra J, Heijnen CJ, Van Vught H. Mechanical ventilation alters the immune response in children without lung pathology. Intensive Care Med (2002) 28:486-92. doi:10.1007/s00134-002-1216-7
61. Kotecha S, Silverman M, Shaw RJ, Klein N. Soluble L-selectin concentration in bronchoalveolar lavage fluid obtained from infants who develop chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed (1998) 78:F143-7. doi:10.1136/fn.78.2.F143
62. Cederqvist K, Sorsa T, Tervahartiala T, Maisi P, Reunanen K, Lassus P, et al. Matrix metalloproteinases-2,-8, and-9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics (2001) 108:686-92. doi:10.1542/peds.108.3.686
63. Sweet DG, McMahon KJ, Curley AE, O'Connor CM, Halliday HL. Type I collagenases in bronchoalveolar lavage fluid from preterm babies at risk of developing chronic lung disease. Arch Dis Child Fetal Neonatal Ed (2001) 84:F168-71. doi:10.1136/fn.84.3.F168
64. Kong MYF, Gaggar A, Li Y, Winkler M, Blalock JE, Clancy JP. Matrix metalloproteinase activity in pediatric acute lung injury. Int J Med Sci (2009) 6:9-17. doi:10.7150/ijms.6.9
65. Srinivasan R, Song Y, Wiener-Kronish J, Flori HR. Plasminogen activation inhibitor concentrations in bronchoalveolar lavage fluid distinguishes ventilator-associated pneumonia from colonization in mechanically ventilated pediatric patients. Pediatr Crit Care Med (2011) 12:21-7. doi:10.1097/PCC.0b013e3181e2a352
66. Lassus P, Nevalainen TJ, Eskola JU, Andersson S. Clara-cell secretory protein in preterm infants' tracheal aspirates correlates with maturity and increases in infection. Pediatr Pulmonol (2000) 30:466-9. doi:10.1002/1099-0496(200012)30:6<466::AID-PPUL5>3.0.CO;2-X
67. Burón E, Garrote JA, Arranz E, Oyágüez P, Fernández Calvo JL, Blanco Quirós A. Markers of pulmonary inflammation in tracheobronchial fluid of premature infants with respiratory distress syndrome. Allergol Immunopathol (Madr) (1999) 27:11-7
68. LeVine AM, Lotze A, Stanley S, Stroud C, O'Donnell R, Whitsett J, et al. Surfactant content in children with inflammatory lung disease. Crit Care Med (1996) 24:1062-7. doi:10.1097/00003246-199606000-00029
69. Kerr MH, Paton JY. Surfactant protein levels in severe respiratory syncytial virus infection. Am J Respir Crit Care Med (1999) 159:1115-8. doi:10.1164/ajrccm.159.4.9709065
70. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child (1996) 75:133-6. doi:10.1136/adc.75.2.133
71. Griese M, Maderlechner N, Ahrens P, Kitz R. Surfactant proteins A and D in children with pulmonary disease due to gastroesophageal reflux. Am J Respir Crit Care Med (2002) 165:1546-50. doi:10.1164/rccm.2107147
72. Said AS, Abd-Elaziz MM, Farid MM, Abd-ElFattah MA, Abdel-Monim MT, Doctor A. Evolution of surfactant protein-D levels in children with ventilator-associated pneumonia. Pediatr Pulmonol (2012) 47:292-9. doi:10.1002/ppul.21548
73. Lassus P, Viinikka L, Ylikorkala O, Pohjavuori M, Andersson S. Pulmonary prostacyclin is associated with less severe respiratory distress in preterm infants. Early Hum Dev (2002) 67:11-8. doi:10.1016/S0378-3782(01)00244-4
74. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, Park DR, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 164:1896-903. doi:10.1164/ajrccm.164.10.2104013
75. Cepkova M, Brady S, Sapru A, Matthay MA, Church G. Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury. Crit Care (2006) 10:R126. doi:10.1186/cc5037
76. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem (2011) 44:601-4. doi:10.1016/j.clinbiochem.2010.12.014
77. Lin WC, Lin CF, Chen CL, Chen CW, Lin YS. Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. Exp Biol Med (Maywood) (2010) 235:57-65. doi:10.1258/ebm.2009.009256
78. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld BJ. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med (2014) 42:691-700. doi:10.1097/01.ccm.0000435669.60811.24
79. Network TARDS. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 342:1301-8. doi:10.1056/NEJM200005043421801
80. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med (2005) 33:1-6; discussion 230-232. doi:10.1097/01.CCM.0000149854.61192.DC
81. Amat M, Barcons M, Mancebo J, Mateo J, Oliver A, Mayoral JF, et al. Evolution of leukotriene B4, peptide leukotrienes, and interleukin-8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: mortality prognostic study. Crit Care Med (2000) 28:57-62. doi:10.1097/00003246-200001000-00009
82. Lee YL, Chen W, Chen LY, Chen CH, Lin YC, Liang SJ, et al. Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. J Crit Care (2010) 25:176.e7-176.e13. doi:10.1016/j.jcrc.2009.05.002
83. Fremont RD, Koyama T, Calfee CS, Wu W, Dossett LA, Bossert FR, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma (2010) 68:1121-7. doi:10.1097/TA.0b013e3181c40728
84. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J (2011) 278:28-45. doi:10.1111/j.1742-4658.2010.07920.x
85. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem (2003) 253:269-85. doi:10.1023/A:1026028303196
86. Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis (2006) 38:867-72. doi:10.1080/00365540600702058
87. Lauhio A, Hästbacka J, Pettilä V, Tervahartiala T, Karlsson S, Varpula T, et al. Serum MMP-8,-9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res (2011) 64:590-4. doi:10.1016/j.phrs.2011.06.019
88. Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, et al. Matrix metalloproteinase-9,-10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care (2009) 13:R158. doi:10.1186/cc8115
89. Hästbacka J, Linko R, Tervahartiala T, Varpula T, Hovilehto S, Parviainen I, et al. Serum MMP-8 and TIMP-1 in critically ill patients with acute respiratory failure: TIMP-1 is associated with increased 90-day mortality. Anesth Analg (2014) 118:790-8. doi:10.1213/ANE.0000000000000120
90. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest (2009) 136:471-80. doi:10.1378/chest.08-2413
91. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury-a review of available pre-clinical models. Curr Med Chem (2008) 15:588-95. doi:10.2174/092986708783769696
92. Han YJ, Park JD, Choi JW, Suh DI, Koh YY. Coagulopathy as a prognostic factor of acute lung injury in children. J Korean Med Sci (2012) 27:1541-6. doi:10.3346/jkms.2012.27.12.1541
93. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front Biosci (Landmark Ed) (2009) 14:150-8. doi:10.2741/3236
94. Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol (2009) 40:123-34. doi:10.1165/rcmb.2008-0241TR
95. Wang T, Liu Z, Wang Z, Duan M, Li G, Wang S, et al. Thrombocytopenia is associated with acute respiratory distress syndrome mortality: an international study. PLoS One (2014) 9:e94124. doi:10.1371/journal.pone.0094124
96. Orwoll B, Spicer A, Alkhouli M, Zinter M, Sapru A. Thrombocytopenia at the onset of pediatric acute respiratory distress syndrome (ARDS) is associated with increased mortality. Pediatr Acad Soc Annu Meet (2015)
97. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 285:L20-8. doi:10.1152/ajplung.00312.2002
98. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med (2007) 35:1821-8. doi:10.1097/01.CCM.0000221922.08878.49
99. Determann RM, Millo JL, Garrard CS, Schultz MJ. Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation. Intensive Care Med (2006) 32:946-7. doi:10.1007/s00134-006-0167-9
100. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 11:23-36. doi:10.1038/nrm2821
101. Jalkanen V, Yang R, Linko R, Huhtala H, Okkonen M, Varpula T, et al. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med (2013) 39:489-96. doi:10.1007/s00134-012-2730-x
102. Gando S, Kameue T, Matsuda N, Sawamura A, Hayakawa M, Kato H. Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation. Inflammation (2004) 28:237-44. doi:10.1023/B:IFLA.0000049049.81688.fe
103. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 285:L514-21. doi:10.1152/ajplung.00442.2002
104. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 344:699-709. doi:10.1056/NEJM200103083441001
105. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, Girbes AR, et al. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost (2013) 11:894-901. doi:10.1111/jth.12179
106. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med (2008) 178:618-23. doi:10.1164/rccm.200803-419OC
107. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med (1997) 156:109-15. doi:10.1164/ajrccm.156.1.9612043
108. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol (1997) 17:501-7. doi:10.1165/ajrcmb.17.4.2253
109. Sato H, Callister MEJ, Mumby S, Quinlan GJ, Welsh KI, DuBois RM, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J (2004) 23:142-5. doi:10.1183/09031936.03.00070303
110. Nathani N, Perkins GD, Tunnicliffe W, Murphy N, Manji M, Thickett DR. Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care (2008) 12:R12. doi:10.1186/cc6785
111. Determann RM, Royakkers AA, Haitsma JJ, Zhang H, Slutsky AS, Ranieri VM, et al. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med (2010) 10:6. doi:10.1186/1471-2466-10-6
112. Nakashima T, Yokoyama A, Ohnishi H, Hamada H, Ishikawa N, Haruta Y, et al. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med (2008) 263:432-9. doi:10.1111/j.1365-2796.2008.01929.x
113. Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hasegawa N, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2004) 286:L1088-94. doi:10.1152/ajplung.00420.2002
114. Kim DH, Kim HS, Shim S, Lee J, Choi CW, Kim EK, et al. Cord blood KL-6, a specific lung injury marker, correlates with the subsequent development and severity of atypical bronchopulmonary dysplasia. Neonatology (2008) 93:223-9. doi:10.1159/111100
115. Ochi F, Fukuda M, Ohmori H, Yano Y, Wakamoto H, Suzuki Y, et al. KL-6 as a biomarker of respiratory complications in severely disabled children. Pediatr Int (2015) 57:439-42. doi:10.1111/ped.12537
116. Al-Salmi QA, Walter JN, Colasurdo GN, Sockrider MM, Smith EO, Takahashi H, et al. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest (2005) 127:403-7. doi:10.1378/chest.127.1.403
117. Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Ann N Y Acad Sci (2000) 923:68-77. doi:10.1111/j.1749-6632.2000.tb05520.x
118. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med (2009) 9:49. doi:10.1186/1471-2466-9-49
119. Lesur O, Langevin S, Berthiaume Y, Légaré M, Skrobik Y, Bellemare JF, et al. Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med (2006) 32:1167-74. doi:10.1007/s00134-006-0235-1
120. Determann R, Royakkers A, Lutter R, JC K, MJ S. Clara cell protein and surfactant protein D plasma levels are associated with clinical outcomes of mechanically ventilated patients. J Pulm Respir Med (2013) 03:1-4. doi:10.4172/2161-105X.1000138
121. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest (2009) 135:1440-7. doi:10.1378/chest.08-2465
122. Abdel-Latif ME, Osborn DA. Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev (2011):CD008308. doi:10.1002/14651858.CD008308.pub2
123. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells (2004) 9:165-74. doi:10.1111/j.1356-9597.2004.00712.x
124. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med (2006) 173:1008-15. doi:10.1164/rccm.200509-1477OC
125. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax (2008) 63:1083-9. doi:10.1136/thx.2008.095588
126. Jabaudon M, Blondonnet R, Roszyk L, Bouvier D, Audard J, Clairefond G, et al. Soluble receptor for advanced glycation end-products predicts impaired alveolar fluid clearance in acute respiratory distress syndrome. Am J Respir Crit Care Med (2015) 192:191-9. doi:10.1164/rccm.201501-0020OC
127. Yerkovich ST, Chang AB, Carroll ML, Petsky HL, Scrivener G, Upham JW. Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation. Respirology (2012) 17:841-6. doi:10.1111/j.1440-1843.2012.02174.x
128. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 137:245-54
129. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl) (1996) 74:13-33. doi:10.1007/BF00202069
130. Moss M, Gillespie MK, Ackerson L, Moore FA, Moore EE, Parsons PE. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. Crit Care Med (1996) 24:1782-6. doi:10.1097/00003246-199611000-00004
131. Conner ER, Ware LB, Modin G, Matthay MA. Elevated pulmonary edema fluid concentrations of soluble intercellular adhesion molecule-1 in patients with acute lung injury: biological and clinical significance. Chest (1999) 116:83S-4S. doi:10.1378/chest.116.suppl_1.83S
132. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care (2008) 12:R41. doi:10.1186/cc6846
133. Calfee CS, Eisner MD, Parsons PE, Thompson BT, Conner ER, Matthay MA, et al. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury. Intensive Care Med (2009) 35:248-57. doi:10.1007/s00134-008-1235-0
134. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest (2010) 137:288-96. doi:10.1378/chest.09-1484
135. Wort SJ, Evans TW. The role of the endothelium in modulating vascular control in sepsis and related conditions. Br Med Bull (1999) 55:30-48. doi:10.1258/0007142991902286
136. Patrick CH, Lazarchick J, Horn BS. Alterations in von Willebrand factor antigen in premature infants with respiratory distress syndrome and chronic lung disease. Ann Clin Lab Sci (1993) 23:39-46
137. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med (2001) 29:2325-31. doi:10.1097/00003246-200112000-00016
138. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med (2004) 170:766-72. doi:10.1164/rccm.200310-1434OC
139. Siemiatkowski A, Kloczko J, Galar M, Czaban S. von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury. Haemostasis (2000) 30:189-95. doi:10.1159/000054134
140. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J (1995) 9:866-73
141. Osaka D, Shibata Y, Kanouchi K, Nishiwaki M, Kimura T, Kishi H, et al. Soluble endothelial selectin in acute lung injury complicated by severe pneumonia. Int J Med Sci (2011) 8:302-8. doi:10.7150/ijms.8.302
142. Okajima K, Harada N, Sakurai G, Soga Y, Suga H, Terada T, et al. Rapid assay for plasma soluble E-selectin predicts the development of acute respiratory distress syndrome in patients with systemic inflammatory response syndrome. Transl Res (2006) 148:295-300. doi:10.1016/j.trsl.2006.07.009
143. Rainer TH, Lam NY, Chan TY, Cocks RA. Early role of neutrophil L-selectin in posttraumatic acute lung injury. Crit Care Med (2000) 28:2766-72. doi:10.1097/00003246-200008000-00014
144. Stengel D, Orth M, Tauber R, Sehouli J, Hentsch S, Thielemann HK, et al. Shed L-selectin (sCD62L) load in trauma patients. J Surg Res (2001) 99:321-7. doi:10.1006/jsre.2001.6173
145. D'Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biol Neonate (1999) 76:266-73. doi:10.1159/000014168
146. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med (1996) 154:555-81. doi:10.1164/ajrccm.154.3.8810589
147. Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis (1993) 148:1646-50. doi:10.1164/ajrccm/148.6_Pt_1.1646
148. Nakano Y, Tasaka S, Saito F, Yamada W, Shiraishi Y, Ogawa Y, et al. Endothelin-1 level in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology (2007) 12:740-3. doi:10.1111/j.1440-1843.2007.01115.x
149. Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology (1996) 87:134-40
150. Strijbos MH, Rao C, Schmitz PIM, Kraan J, Lamers CH, Sleijfer S, et al. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost (2008) 100:642-7. doi:10.1160/TH08-02-0122
151. Sapru A, Calfee CS, Liu KD, Kangelaris K, Hansen H, Pawlikowska L, et al. Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome. Intensive Care Med (2015) 41:470-8. doi:10.1007/s00134-015-3648-x
152. Shirahata A, Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, et al. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr (2014) 173:303-11. doi:10.1007/s00431-013-2155-8
153. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg (2012) 72:1150-7. doi:10.1097/TA.0b013e3182516ab5
154. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki TST. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost (2015) 13:508-19. doi:10.1111/jth.12841
155. Parikh SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence (2013) 4:517-24. doi:10.4161/viru.24906
156. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med (2013) 187:736-42. doi:10.1164/rccm.201208-1460OC
157. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA, NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med (2012) 40:1731-7. doi:10.1097/CCM.0b013e3182451c87
158. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock (2008) 29:656-61. doi:10.1097/shk.0b013e31815dd92f
159. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis (1993) 147:218-33. doi:10.1164/ajrccm/147.1.218
160. Mok YH, Lee JH, Rehder KJ, Turner DA. Adjunctive treatments in pediatric acute respiratory distress syndrome. Expert Rev Respir Med (2014) 8:703-16. doi:10.1586/17476348.2014.948854
161. Sun YZ, Gao YL, Yu QX, Wang J, Xia YH, Lin HY, et al. Assessment of acute lung injury/acute respiratory distress syndrome using B-type brain natriuretic peptide. J Int Med Res (2015) 43:802-8. doi:10.1177/0300060515586245
162. Determann RM, Royakkers AA, Schaefers J, de Boer AM, Binnekade JM, van Straalen JP, et al. Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients-relation to tidal volume size and development of acute respiratory distress syndrome. BMC Pulm Med (2013) 13:42. doi:10.1186/1471-2466-13-42
163. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmor D, et al. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest (2007) 131:964-71. doi:10.1378/chest.06-1247
164. Lee KS, Choi YH, Kim YS, Baik SH, Oh YJ, Sheen SS, et al. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Respir Med (2008) 102:464-9. doi:10.1016/j.rmed.2007.10.001
165. Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol (2002) 161:1783-96. doi:10.1016/S0002-9440(10)64455-0
166. Vane JR, Anggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med (1990) 323:27-36. doi:10.1056/NEJM199007053230106
167. Slotman GJ, Burchard KW, Gann DS. Thromboxane and prostacyclin in clinical acute respiratory failure. J Surg Res (1985) 39:1-7. doi:10.1097/CCM.0b013e3181aee5dd
168. Deby-Dupont G, Braun M, Lamy M, Deby C, Pincemail J, Faymonville ME, et al. Thromboxane and prostacyclin release in adult respiratory distress syndrome. Intensive Care Med (1987) 13:167-74. doi:10.1007/BF00254700
169. Huang YS, Li A, Yang ZC. Roles of thromboxane and prostacyclin in the pathogenesis of acute respiratory failure in burn patients combined with inhalation injury. Burns (1992) 18:452-5. doi:10.1016/0305-4179(92)90176-U
170. Antonelli M, Bufi M, De Blasi RA, Crimi G, Conti G, Mattia C, et al. Detection of leukotrienes B4, C4 and of their isomers in arterial, mixed venous blood and bronchoalveolar lavage fluid from ARDS patients. Intensive Care Med (1989) 15:296-301. doi:10.1007/BF00263864
171. Stephenson AH, Lonigro AJ, Hyers TM, Webster RO, Fowler AA. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev Respir Dis (1988) 138:714-9. doi:10.1164/ajrccm/138.3.714
172. Masclans JR, Sabater J, Sacanell J, Chacon P, Sabin P, Roca O, et al. Possible prognostic value of leukotriene B(4) in acute respiratory distress syndrome. Respir Care (2007) 52:1695-700
173. Bernard GR, Korley V, Chee P, Swindell B, Ford-Hutchinson AW, Tagari P. Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am Rev Respir Dis (1991) 144:263-7. doi:10.1164/ajrccm/144.2.263
174. Davidson D, Drafta D, Wilkens BA. Elevated urinary leukotriene E4 in chronic lung disease of extreme prematurity. Am J Respir Crit Care Med (1995) 151:841-5. doi:10.1164/ajrccm.151.3.7881680
175. Joung KE, Kim HS, Lee J, Shim GH, Choi CW, Kim EK, et al. Correlation of urinary inflammatory and oxidative stress markers in very low birth weight infants with subsequent development of bronchopulmonary dysplasia. Free Radic Res (2011) 45:1024-32. doi:10.3109/10715762.2011.588229
176. Sheikh S, Null D, Gentile D, Bimle C, Skoner D, McCoy K, et al. Urinary leukotriene E(4) excretion during the first month of life and subsequent bronchopulmonary dysplasia in premature infants. Chest (2001) 119:1749-54. doi:10.1378/chest.119.6.1749
177. Negi R, Pande D, Karki K, Kumar A, Khanna RS, Khanna HD. A novel approach to study oxidative stress in neonatal respiratory distress syndrome. BBA Clin (2015) 3:65-9. doi:10.1016/j.bbacli.2014.12.001
178. Cardinal-Fernández P, Ferruelo A, Esteban A, Lorente JA. Characteristics of microRNAs and their potential relevance for the diagnosis and therapy of the acute respiratory distress syndrome: from bench to bedside. Transl Res (2015) 169:102-11. doi:10.1016/j.trsl.2015.11.004
179. Angulo M, Lecuona E, Sznajder JI. Role of microRNAs in lung disease. Arch Bronconeumol (2012) 48:325-30. doi:10.1016/j.arbres.2012.04.011
180. Pagdin T, Lavender P. MicroRNAs in lung diseases. Thorax (2012) 67:183-4. doi:10.1136/thoraxjnl-2011-200532
181. McVey M, Tabuchi A, Kuebler WM. Microparticles and acute lung injury. Am J Physiol Lung Cell Mol Physiol (2012) 303:L364-81. doi:10.1152/ajplung.00354.2011
182. Guervilly C, Lacroix R, Forel JM, Roch A, Camoin-Jau L, Papazian L, et al. High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care (2011) 15:R31. doi:10.1186/cc9978
183. Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB. Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2009) 297:L1035-41. doi:10.1152/ajplung.00214.2009
184. Monsel A, Zhu Y, Gennai S, Hao Q, Hu S, Rouby JJ, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med (2015) 192:324-36. doi:10.1164/rccm.201410-1765OC
185. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science (2004) 303:1532-5. doi:10.1126/science.1092385
186. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest (2012) 122:2661-71. doi:10.1172/JCI61303
187. Hamaguchi S, Hirose T, Matsumoto N, Akeda Y, Irisawa T, Seki M, et al. Neutrophil extracellular traps in bronchial aspirates: a quantitative analysis. Eur Respir J (2014) 43:1709-18. doi:10.1183/09031936.00139813
188. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med (2013) 187:160-9. doi:10.1164/rccm.201206-1037OC
189. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med (2014) 2:611-20. doi:10.1016/S2213-2600(14)70097-9
190. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med (2011) 365:1088-98. doi:10.1056/NEJMoa1106469